|
|
|
|
|
|
Free Newsletters
Archive
My eNewsletters
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Login
Become a Member
Discussion Forums
FAQ
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Career Definitions
Labor Market Reports
Education & Training
Regions
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
OXiGENE (OXGN) Appoints Dr. Peter J. Langecker as Chief Development Officer
6/17/2009
WALTHAM, Mass., June 17, 2009 (GLOBE NEWSWIRE) -- OXiGENE, Inc., a clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced the appointment of Peter J. Langecker, M.D., Ph.D., as Executive Vice President and Chief Development Officer. Dr. Langecker will oversee the development of OXiGENE's drug candidates, ZYBRESTAT(tm) for oncology, ZYBRESTAT for ophthalmology, and OXi4503. Dr. Langecker is scheduled to begin his position with OXiGENE on June 29, 2009.
|
|
|
|
|
|
|
|
|
|
|
|